Encouragingly, analysis of tumour samples pre-and post-treatment showed that in most cases there was an increase in CD8+ cytotoxic T cells and effector T cells, with a down-regulation of suppressive TAMs and Tregs, and results of ongoing Phase II studies are eagerly anticipated. The gene discussed is CD8A; the disease is neoplasm.